The Industry Special Interest Group (I-SIG) members are a diverse group of researchers from the pharmaceutical and device industry, academia and consulting, who share a common interest in the application of patient-centered outcomes, including health-related quality of life (HRQOL), in research important to industry.
We are interested in innovative methods and research in patient-centered outcomes measurement for use in research important to industry.
The purpose of the I-SIG is to synthesize, share, promote and educate on industry-related patient-centered outcomes research by bringing individuals together who are interested in topics of joint interest to industry and ISOQOL.
Our specific goals are to:
Watch here for announcements of current I-SIG initiatives.
2016 Annual Symposium:
Topic to be determined
Past Symposium Topics:
2015: Bring Your Own Device (BYOD): trends, best practices, challenges….where do PRO measures go from here?
2014: Advancing Measurement Science Beyond PROs: Patient-Centeredness and Validity Across All Clinical Outcome Assessments
2013: Innovations for Patient Engagement in Health Outcomes Development, Selection and Measurement: Opportunities and Limitations
2012: Perspectives on Mixed Methods to Assess Content Validity of a Patient Reported Outcome
2011: To Qualify or Not to Qualify: Benefits and Challenges of PRO Instrument Qualification from Industry, Academic, and Regulatory Perspectives
We encourage active communication between members.
Watch here for announcements of upcoming webinars.
Interpretation of PRO Data within Clinical Trials (not available via website)
Current Chair: Josephine Norquist
Current Co-Chair: Emuella Flood
Josephine Norquist is the Patient-Reported Outcome (PRO) & Study Endpoint Group Lead at Merck Sharp & Dohme, Corp. In her role Josephine leads, develops and implements endpoint strategies for global clinical trials across several therapeutic areas. She leads endpoint strategies and interactions with agencies on Clinical Outcome Assessments (COAs) to be used to support labeling claims and/or HTA/reimbursement. She is one of the Merck’s representatives on the C-PATH PRO Consortium, chairs the ISOQOL Industry SIG (previously known as IAC) and is part of the Study Endpoints Special Interest Group within DIA. Before joining Merck, she worked at the University of Oxford, Institute of Health Sciences, Department of Public Health in Oxford, U.K., where she was a Research Officer responsible for statistical analyses, report writing, and manuscript preparation in the areas of patient-reported outcomes. Prior to that, she was a Research Statistician at the Center on Outcomes, Research and Education (CORE) at Evanston Northwestern Healthcare in Evanston, IL. She earned her B.S. in Statistics and Economics from the Universita’ degli Studi di Palermo (Italy) and her M.S. in Statistics from Northwestern University (IL). Since completing her graduate degree, Josephine’s primary focus has been in the development and validation of PRO/COA measures, to support both regulatory and reimbursement requirements. She has written many peer-reviewed journal articles and research report summaries on PRO measures and has created several endpoint dossiers for submissions to regulatory agencies.
Emuella Flood is a Senior Principal within ICON Clinical Outcomes Assessments (COA) and leads the US East Coast COA team in Gaithersburg, Maryland. She began her career in COA research nearly 20 years ago at MEDTAP International / UBC (now Evidera) before joining Oxford Outcomes in 2006 and ICON in 2011 through acquisition. Emuella has directed the development of COAs, patient preference/conjoint and satisfaction surveys, and patient and caregiver-reported burden of illness surveys for both adult and pediatric populations and across numerous therapeutic areas. She has extensive experience in qualitative research and has presented on best practices at COA professional conferences. In addition to co-chairing the I-SIG, Emuella leads the DIA Study Endpoints Community Educational Series Committee, is a member of the Patient Preference Methodology Working Group of the Medical Device Innovation Consortium (MDIC), and is on the editorial board of The Patient. She has contributed to over 80 peer-reviewed papers and abstracts.